Date: 2016-08-24
Type of information: Nomination
Compound:
Company: Txcell (France)
Therapeutic area: Autoimmune diseases – Inflammatory diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On August 24, 2016, TxCell announces the appointment to its Scientific Advisory Board (SAB) of Olivier Danos, PhD, Senior Vice President of Cell and Gene Therapy at Biogen and a world-leading expert in the field of Gene Therapy for hematological and neurological diseases. Dr. Danos has led Biogen’s gene therapy research group, a team dedicated to identifying and developing new technologies for gene transfer and genome engineering, since 2014. Prior to Biogen, Dr. Danos served as Senior Vice President, Molecular Medicine, Synthetic Biology and Gene Regulation, at Kadmon Pharmaceuticals, from 2011 to 2014. In this role, he was instrumental in assembling a gene therapy program and a technology platform for the development of controllable gene expression systems. Prior to Kadmon, Dr. Danos was the Director of the Gene Therapy Consortium at University College, London, and led a gene therapy research team at the Necker Hospital - Enfants Malades in Paris. His other previous appointments include Scientific Director of Généthon and Senior Research Director with the CNRS in France.
Financial terms:
Latest news:
